Last updated on August 2018

PGE1 as Additive Anticoagulant in ECMO-Therapy


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Extracorporeal Membrane Oxygenation | ADULT RESPIRATORY DISTRESS SYNDROME
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • minimum age 18 years
  • Veno-Venous- ECMO
  • Minimum of 24h planned ECMO- therapy

Exclusion Criteria:

  • Long- term therapy with other antiplatelet drugs including Acetyl Salicylic Acid
  • known Heparin induced thrombocytopenia
  • Bleeding diathesis = contraindication for heparin (e.g. GI-bleeding, Intracerebral bleeding)
  • Platelets < 50 G/L
  • Thromboplastin time < 50%
  • Pregnancy
  • Patient < 18 years
  • prothrombin time <50%

Drop out criteria:

  • Major bleeding (from Type 3 bleeding; see "primary objective")
  • Occurrence of HIT (4 T- Score: Number of platelets, development over time, manifestation of thrombosis, other reasons for thrombocytopenia [10])
  • Plt < 50 G/l

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.